Kelly Timothy P 4
4 · Homology Medicines, Inc. · Filed Jan 12, 2022
Insider Transaction Report
Form 4
Kelly Timothy P
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2022-01-01+3,630→ 3,630 total - Sale
Common Stock
2022-01-05$3.78/sh−1,406$5,315→ 2,224 total - Exercise/Conversion
Restricted Stock Units
2022-01-01−3,630→ 7,370 total→ Common Stock (3,630 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
- [F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.79. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
- [F4]The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date.